Chief Development Officer
Current
Sep 2022 - Present
AeroLeads people directory · profile
Dr. William Sheridan, Mb Bs, Fracp, Facp Email & Phone Number
Chief Development Officer at BioCryst Pharmaceuticals
at
BioCryst Pharmaceuticals, Inc.
2 work emails found
@biocryst.com
2 phones found area 205
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Chief Development Officer at BioCryst Pharmaceuticals
Location
Santa Barbara, California, United States
Who is Dr. William Sheridan, Mb Bs, Fracp, Facp? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Dr. William Sheridan, Mb Bs, Fracp, Facp is listed as Chief Development Officer at BioCryst Pharmaceuticals at BioCryst Pharmaceuticals, Inc., based in Santa Barbara, California, United States. AeroLeads shows a work email signal at biocryst.com, phone signal with area code 205, and a matched LinkedIn profile for Dr. William Sheridan, Mb Bs, Fracp, Facp.
Dr. William Sheridan, Mb Bs, Fracp, Facp previously worked as Chief Development Officer at Biocryst Pharmaceuticals, Inc. and Chief Medical Officer at Biocryst Pharmaceuticals, Inc.. Dr. William Sheridan, Mb Bs, Fracp, Facp holds Mb Bs, Medicine from University Of Melbourne.
Company email context
Email format at BioCryst Pharmaceuticals, Inc.
This section adds company-level context without repeating Dr. William Sheridan, Mb Bs, Fracp, Facp's masked contact details.
*@biocryst.com
71% confidence
AeroLeads found 2 current-domain work email signals for Dr. William Sheridan, Mb Bs, Fracp, Facp. Compare company email patterns before reaching out.
Profile bio
About Dr. William Sheridan, Mb Bs, Fracp, Facp
As the Chief Development Officer at BioCryst, I am a seasoned biotechnology professional with a focus on driving the growth and success of our portfolio of investigational drugs for rare diseases, with the goals of meeting real medical needs and optimizing corporate value.BioCryst’s structure-guided approach to drug design uses an iterative process to increase selectivity and enable efficient, rapid drug development. We concentrate on developing drugs for rare diseases in which patient needs are still largely unmet. BioCryst discovered and is developing BCX10013, a novel, oral, potent and selective small molecule Factor D inhibitor that could offer significant therapeutic advances for patients with complement-mediated diseases.At BioCryst, our team of Owners has successfully developed the first oral plasma kallikrein inhibitor, Oraldeyo (berotralstat), indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Prior to joining BioCryst, I held a 14-year tenure at Amgen, where I led or supervised several preclinical and clinical development phase product development teams, and later organized and led the company’s Medical Affairs functions in the US and Europe, making significant contributions to the successful launch of many innovative new drugs, including Aranesp®, Enbrel®, Kineret®, Neulasta®, and Sensipar®, organized the Global Health Economics and Outcomes Research function. I earned a MB BS degree (MD equivalent) at the University of Melbourne in Victoria, Australia. I’m a board-certified Fellow of the Royal Australasian College of Physicians, with a subspecialty in medical oncology, and a Fellow of the American College of Physicians.
Listed skills include Oncology, Biotechnology, Clinical Trials, Drug Development, and 6 others.
Current workplace
Dr. William Sheridan, Mb Bs, Fracp, Facp's current company
Company context helps verify the profile and gives searchers a useful next step.
18 roles
Dr. William Sheridan, Mb Bs, Fracp, Facp work experience
A career timeline built from the work history available for this profile.
Chief Medical Officer
Jul 2008 - Sep 2022
Sole Proprietor
Wps Biotech Consulting
Independent Biotechnology consulting
Nov 2007 - Jun 2008
Vice President, North American Medical Affairs
Leaderhsip of Medical Affairs for all therapeutic areas and functions supporting US and Canadian businesses. Drove final recommendation for and executive endorsement of single medical platform, and led NAMA function during reorganization into single platform model.
Jul 2007 - Nov 2007
Vice President, International Medical Affairs
Leadership of regional International (supporting European and Australian) Medical Affairs organization across all therapeutic areas. Matrix leadership of 15 country affiliate medical directors. Established and co-chaired regional protocol review committee. Drove inaugural global medical leadership meeting. Change agent - drove analysis and recommendation.
Feb 2005 - Jun 2007
Vice President, Global Health Economics And Outcomes Research
Consolidated and reorganized dispersed technical groups into a single global organization. Leadership of new group.
Jan 2004 - Feb 2005
Vice President, Us Medical Affairs
Created, built, and led US Medical Affairs organization covering medical and scientific support for all marketed and late stage products.
Jan 2002 - Dec 2003
Vice President, Product Development
Leadership of group of global product development leaders in oncology therapeutic area.
Mar 2000 - Dec 2001
Senior Director, Product Development
Global Product Development Leader for (sequentially) Megakayrocyte Growth and Development Factor (MGDF) and Abarelix
Jul 1998 - Feb 2000
Director, Clinical Hematology
Global Product Development Leader for (sequentially) Stem Cell Factor (SCF) and Megakaryocyte Growth and Development Factor (MGDF)
Mar 1993 - Jun 1998
Head, Bone Marrow Transplant Service
Led BMT and PBPC services in integrated hematology-oncology department at major teaching hospital.
Jan 1991 - Mar 1993
Assistant Medical Oncologist
Member of leading full-service integrated hematology - medical oncology department in academic medical institution in Melbourne, Victoria, Australia. Department headed by Prof. Richard Fox. Developed successful program in bone marrow and peripheral blood transplantation (BMT and PBPC) from the ground up. Principal investigator in studies of granulocyte.
Aug 1986 - Mar 1993
Research Fellow
Laboratory and clinical research fellowship in Division of Hematology and Medical Oncology, Department of Medicine. First cinical fellow in the history of the division. Supervisor - Dr. David Gordon.
Feb 1985 - Aug 1986
Locum Consultant Physician
Prince Henry'S Hospital And Royal Hobart Hospital
Consultant physician in a variety of locum roles, including intensive care (Prince Henry's Hospital, Melbourne, Victoria), and hematology - medical oncology (Royal Hobart Hospital, Hobart, Tasmania).
Feb 1984 - Jan 1985
Hematology - Medical Oncology Registrar (Fellow)
Prince Henry'S Hospital
Fifth and sixth postgraduate years, completion of internal medicine training requirements for fellowship of the Royal Australasian College of Phycisians, subspecialty Medical Oncology. Senior house physician for comprehensive teaching hospital hematology and medical oncology department. Supervisor - Dr. Graeme Brodie.
Feb 1982 - Jan 1984
Internal Medicine Registrar (Fellow)
Prince Henry'S Hospital
Fourth post-graduate year; internal medicine training program; rotations in nephrology and general medicine, including two country hospital locations (feeder hospitals for Prince Henry's).
Feb 1981 - Jan 1983
Internal Medicine Resident
Prince Henry'S Hospital
Second and third postgraduate years post medical degree; internal medicine training program. Included rotations in general medicine, hematology and medical oncology, dialysis, & emergency medicine.
Feb 1979 - Jan 1981
Feb 1978 - Jan 1979
2 education records
Dr. William Sheridan, Mb Bs, Fracp, Facp education
Mb Bs, Medicine
University Of Melbourne
Mb Bs, Medicine
University Of Melbourne
FAQ
Frequently asked questions about Dr. William Sheridan, Mb Bs, Fracp, Facp
Quick answers generated from the profile data available on this page.
What company does Dr. William Sheridan, Mb Bs, Fracp, Facp work for?
Dr. William Sheridan, Mb Bs, Fracp, Facp works for BioCryst Pharmaceuticals, Inc..
What is Dr. William Sheridan, Mb Bs, Fracp, Facp's role at BioCryst Pharmaceuticals, Inc.?
Dr. William Sheridan, Mb Bs, Fracp, Facp is listed as Chief Development Officer at BioCryst Pharmaceuticals at BioCryst Pharmaceuticals, Inc..
What is Dr. William Sheridan, Mb Bs, Fracp, Facp's email address?
AeroLeads has found 2 work email signals at @biocryst.com for Dr. William Sheridan, Mb Bs, Fracp, Facp at BioCryst Pharmaceuticals, Inc..
What is Dr. William Sheridan, Mb Bs, Fracp, Facp's phone number?
AeroLeads has found 2 phone signal(s) with area code 205 for Dr. William Sheridan, Mb Bs, Fracp, Facp at BioCryst Pharmaceuticals, Inc..
Where is Dr. William Sheridan, Mb Bs, Fracp, Facp based?
Dr. William Sheridan, Mb Bs, Fracp, Facp is based in Santa Barbara, California, United States while working with BioCryst Pharmaceuticals, Inc..
What companies has Dr. William Sheridan, Mb Bs, Fracp, Facp worked for?
Dr. William Sheridan, Mb Bs, Fracp, Facp has worked for Biocryst Pharmaceuticals, Inc., Wps Biotech Consulting, Amgen Inc., Royal Melbourne Hospital, and Emory University School Of Medicine.
How can I contact Dr. William Sheridan, Mb Bs, Fracp, Facp?
You can use AeroLeads to view verified contact signals for Dr. William Sheridan, Mb Bs, Fracp, Facp at BioCryst Pharmaceuticals, Inc., including work email, phone, and LinkedIn data when available.
What schools did Dr. William Sheridan, Mb Bs, Fracp, Facp attend?
Dr. William Sheridan, Mb Bs, Fracp, Facp holds Mb Bs, Medicine from University Of Melbourne.
What skills is Dr. William Sheridan, Mb Bs, Fracp, Facp known for?
Dr. William Sheridan, Mb Bs, Fracp, Facp is listed with skills including Oncology, Biotechnology, Clinical Trials, Drug Development, Clinical Development, Cross Functional Team Leadership, Team Leadership, and Strategic Leadership.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial